National Kidney Foundation Spring Clinical Meetings

National Kidney Foundation Spring Clinical Meetings

Source:

Askanase A, et al. Abstract #283. Presented at: National Kidney Foundation Spring Clinical Meetings (virtual meeting); April 6-10, 2021.

Disclosures: Healio Nephrology was unable to determine relevant financial disclosures prior to publication.
April 08, 2021
1 min read
Save

Voclosporin may effectively treat lupus nephritis at all stages of disease progression

Source:

Askanase A, et al. Abstract #283. Presented at: National Kidney Foundation Spring Clinical Meetings (virtual meeting); April 6-10, 2021.

Disclosures: Healio Nephrology was unable to determine relevant financial disclosures prior to publication.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Adding the calcineurin inhibitor voclosporin to the standard of care was effective in treating lupus nephritis across all biopsy classes, according to pooled data from the AURA-LV and AURORA trials.

Healio Nephrology previously reported on phase 3 results of the AURORA trial, which also demonstrated the drug was superior to standard of care (mycophenolate mofetil and low-dose steroids) in generating complete renal response; this analysis extends those findings through examining efficacy across disease stages.

Biopsy tools
Source: Adobe Stock

For the post-hoc analysis, researchers utilized data from 532 patients who were treated with either voclosporin (23.7 mg twice daily) or placebo.

Results pointed to the efficacy of treatment with voclosporin across biopsy classes, with the odds ratios for complete renal response for voclosporin vs. placebo to be 4.26 for pure class III, 2.59 for pure class IV, 1.5 for pure class V and 2.68 for mixed class III/IV and V.

“People with [lupus nephritis] LN can sometimes have a delay in diagnosis and often incomplete responses to treatment, increasing their likelihood of kidney damage and other disease complications,” Anca D. Askanase, MD, MPH, founder and director of Columbia University Irving Medical Center’s Lupus Center and the director of rheumatology clinical trials, said in a related press release. “These data support Lupkynis’ [voclosporin, Aurinia Pharmaceuticals Inc.] potential as an important tool to control LN regardless of the disease classification.”

The FDA approved Lupkynis for the treatment of adult patients with lupus nephritis in January 2021.